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Abstract The study of the genetic profile of
centenarians aims to identify the genes and allelic
variants which may influence a greater life expec-
tancy and that can be considered as predisposing
factors associated to the aging diseases, such as
Alzheimer. Centenarians, that represent a cohort of
selected survivors, show an hypercoagulability state
characterised by striking signs of high coagulation
enzyme activity, as directly assessed by the tested
higher plasma level of some important factors
involved in the haemostasis balance. Anyway, these
individuals seem to have a reduced susceptibility to
dementia, as well as to cardiovascular events. In this
study we analyze the frequencies of Leiden Factor V
polymorphism (G1691A), and G20210A of pro-
thrombin (FII) in three cohorts of subjects: patients
with Alzheimer’s disease (unsuccessful aging), nona-
genarians (successful aging) and young healthy
controls, to assess whether allelic variants associated
to the modification of haemostatic system function,
may play a role in the protection or susceptibility to
Alzheimer disease, as well as to reach a successful
aging. No significant differences were observed in the
frequencies of the three groups studied. These results
indicate that the presence or absence of the gene
variants examined did not influence the achievement
of advanced age and are not risk factors for Alzhei-
mer’s disease. The state of hypercoagulability and the
possession of these risk alleles appear to be compat-
ible with the achievement of longevity and are not
implied as risk factors in Alzheimer disease
development.
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Introduction
Aging is characterised by a progressive loss of ability
to effectively interact with the environmental stimuli
and it is accompanied by progressive modification
and adaptations that are influenced by lifestyle and
genetic background of the single individual, condi-
tioning the reaching of a successful or an unsuccess-
ful ageing. The preservation of cognitive functioning
is an essential component of successful aging. The
ability to distinguish those individuals who maintain
cognitive health into advanced age from those who
will develop a cognitive decline may influence public
health efforts, in order to prevent or delay the onset of
cognitive impairment in old age.
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There is a growing evidence implicating vascular
risk factors and related subclinical cerebrovascular
damage in cognitive impairment and dementia, but
the role of inflammation in vascular and neurode-
generative processes is poorly understood. In the
Alzheimer Disease (AD), and in other neurodegen-
erative diseases as well, it is hypothesized that an
alteration of the neurovascular unit, which is the
functional unit encompassing vascular cells, astro-
cytes and perivascular neurons, is an early event in
the pathogenesis of the disease (Iadecola 2004).
Dysfunction of the neurovascular unit results in an
impaired blood brain barrier functions, dysregulation
of cerebral blood flow and impairment of beta-
amyloid (A-beta) clearance with increase of oligo-
mers and soluble A-beta forms (Zlokovic 2008).
In this view, it might be of some interest the
hypothesis that one of the constant feature of ageing,
the progressive increase of concentrations of some
coagulation factors, such as factor VII, factor VIII
and fibrinogen, the increase of platelets activity and
fibrinolysis impairment, might play a role in the well
known age associated increased susceptibility to
cardiovascular and thromboembolic diseases, as well
as, in the pathogenesis of dementia. Some inherited
prothrombotic variants of coagulation proteins, such
as factor V (FV) Leiden and prothrombin G20210A
polymorphism, may play a key role in this scenario.
Leiden Factor V is present in 20% of patients with
venous thrombosis and in over half of probands in
selected families with thrombophilia. This means that
it represents the most common genetic abnormality in
patients with thrombosis (Rosendaal et al. 1995).
In particular, the heterozygous form of Leiden
factor V increases the risk of thrombosis 3–8x, while
the homozygous form presents a risk which may be up
to 80 times greater (Koster et al. 1993; Ridker et al.
1995; Anderson et al. 1991). Furthermore, the muta-
tion G?A at the position 2010 in the 30-untranslated
region of the prothrombin gene is associated with an
increased level of prothrombin and such an increased
risk of developing thrombosis (Poort et al. 1996). In
spite of the potential role that prothrombotic variants
of genes, coding for the coagulation factors, might
play in Alzheimer’s disease (AD) susceptibility
(Gupta et al. 2005; Cortes-Canteli et al. 2010), very
few studies have been performed on the association
between coagulation gene polymorphisms and AD
(Gerardino et al. 2006).
On the other hand, centenarians, that represent a
cohort of selected survivors who benefit of a delay in
the onset of diseases, that often cause mortality in the
general population at significantly younger ages
(Candore et al. 2006), show an hypercoagulability
characterised by striking signs of high coagulation
enzyme activity, as assessed directly by measuring
factor VIIa plasma level or, indirectly, by measuring
the peptides released following the activation of
prothrombin, or factors IX and X, both well docu-
mented (Mari et al. 2008). However, these individ-
uals seem to have a reduced susceptibility to
dementia, as well as to cardiovascular events
(Franceschi et al. 1995).
Considering the role that a genetically determined
hypercoagulability might play in the cognitive decline
associated with AD, we analyzed the frequencies of
polymorphisms G1691A of Factor V and G20210A of
prothrombin (FII) in patients with AD and in subjects
of age[90 years old, which having overcame the risk
of ADs, might be considered the better model to
assess whether these allelic variants are associated to
the modification of haemostatic system function and if
they have a role in the protection or susceptibility to
the onset of AD. In addition, allele and genotype
frequencies of patients and nonagenarians have been
compared to those ones of a group composed by
young healthy controls, in order to evaluate the
possible effect of age stratification on genetic fre-
quencies modification for the analysed genes.
Materials and methods
Subjects
This study included three groups of subjects.
AD patients 95 subjects (Northern Italy; mean age
70.3; mean onset age 68.9; 23 males and 72 females)
affected by AD. Diagnosis of probable AD had been
performed according to standard clinical procedures.
The DMS IV and NINCDS-ADRDA criteria were
applied to obtain the clinical diagnosis of AD
(Mckhann et al. 1984). Cognitive performances and
alterations were measured according to the Mini
Mental State Evaluation (MMSE) and the Global
Deterioration Scale (GDS) (Doody et al. 2001). All
AD cases were defined as sporadic because the family
history did not mention any first-degree relative with
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dementia. Age at onset was defined as the age when
memory loss was first noticed by relatives, besides,
79 of AD patients showed clinical onset of the
disease after 65 years of age (late-onset AD, LOAD)
and 16 before this age (early onset AD, EOAD).
Nonagenarians. A group of 106 individuals of age
[90 years old, matched for ethnicity and gender
(Northern Italy; 21 males and 85 females) with
control subjects. Cognitive status of these subjects
was assessed by administration of the Mini-Mental
State Examination (Mean score 28 ± 2; score for
inclusion as normal control subjects [24) (Cockrell
and Folstein 1988).
Young subjects. A group composed by 65 healthy
subjects aged between 20 and 50 years old matched
for ethnicity and gender (Northern Italy; 18 males
and 47 females) with nonagenarians subject;
Written informed consent for the study’s enrolling
and for personal data management was obtained from
controls and relatives of nonagenarians and AD
patients according to Italian laws.
Blood specimens were collected in tripotassium
EDTA sterile tubes, DNA extracted (Miller et al.
1988) and processed for genotyping as described
below.
G1691A of FV and 20210GA of FII allele
discrimination
The two polymorphisms: G1691A (FV Leiden) and
G20210A were typed by two pre-made Taqman Real-
Time PCR allelic discrimination assays, by Applied
Biosystems.
Briefly, 10 ng of DNA for each sample were used
in a PCR reaction, containing 19 optimized master
mix and 19 specific primers/probes mix assay,
according to manufactory protocol in a final volume
of 25 ll.
For each polymorphism, two identical probes,
except for the central nucleotide that specifically
recognizes the single nucleotide polymorphism
(SNP) were used, each one labelled at the 50
extremity with different dyes, FAM and VIC in this
case and at the 30 extremity with a quencher dye, that
in this case was the Minor Groove Binder (MGB)
dye.
Then, the amplification was performed in 7300
Real-Time ABI Prism PCR System (Applied Biosys-
tems, USA), using a standard amplification protocol
(1 cycle of 20 at 50C; 1 cycle of 100 at 95C and 40
cycles of 1500at 95C plus 1500at 60C), and the results
were available in the report sheet of 7300 System
SDS v1.3 Software.
Moreover, samples were graphically grouped in 3
genotypic clusters, easily recognizable in the Allelic
Discrimination plot on the basis of the two probe’s
fluorescence intensity emissions, whereas the uncer-
tain cases were also evaluated for the grow up of the
fluorescence emission curve of each dyes on the
components sheet.
Statistical analysis
The data were tested for goodness of fit between the
observed and expected genotype (3 9 2 tables) and
allele (2 9 2 tables) frequencies. Fisher’s exact tests
were performed to calculate significant different
genotype or allelic distributions between AD patients,
nonagenarians and matched controls. It was accepted
a significance with P values \ 0.05. The Hardy–
Weinberg equilibrium was tested using the Pearson
test.
Results and discussion
The goal of the present study is to assess whether
allelic variants, G1691A Factor V (Leiden FV) and
G20210A prothrombin single nucleotide polymor-
phisms (SNP), associated to the modification of
haemostatic system function, may play a role in the
protection or susceptibility to AD, as well as to reach
a successful aging.
Table 1 shows the genotypes and alleles frequen-
cies for Leiden FV in our sample of 95 patients with
AD, 106 nonagenarians and 65 healthy young
subjects.
No significant differences were observed in the
genotype and allele frequencies among the three
groups studied (P [ 0.05). However, we observed a
slight increase of the mutated allele frequency, due to
an increase of the heterozygosis condition in the
elderly and in the AD patients, where the mutated
allele is more common in comparison with young
individuals.
Mari et al. (1996), previously described similar
allele frequency for this mutation in Italian centenar-
ians without any history of thrombotic events, also in
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five centenarians carrying the factor V mutation,
exposed during their life to circumstantial risk factors
for thrombosis.
Moreover, studies on octogenarians and centenar-
ians in Europe suggest a normal life span expectancy
for Leiden FV carriers. In 3 studies of people older
than 80 years old, living in Italy (Mari et al. 1996),
Denmark (Rees et al. 1997) and the United Kingdom
(Kristensen et al. 1998), the prevalence of the Leiden
FV gene in the elderly population was similar to its
prevalence in the general population. If Leiden FV
carriers were dying at a younger age for VTE events,
then the expected prevalence of the FV Leiden allele
in an older age group should be lower. In a population
based mortality study of octogenarians living in
Leiden, 660 patients were observed for 10 years. The
relative risk of mortality in Leiden FV carriers was
identical to that one observed in the no carriers
(Heijmans et al. 1998).
Our results seem to confirm the above mentioned
data and demonstrate that Leiden FV variant seems
do not play a role as susceptibility factor for AD.
Similar results were obtained typing the prothrom-
bin G20210A polymorphism. The genotypic and
allelic distribution of the single nucleotide polymor-
phism (SNP), located at the position G 20210A of the
prothrombin (FII) gene, shows no statistical differ-
ences between young subjects, nonagenarians and
patients with AD (Table 2).
As well known, a mutation in the 30 untranslated
region of the prothrombin gene (G20210A), associ-
ated with higher plasma levels of prothrombin, is a
common genetic risk factor for venous thrombosis
(Poort et al. 1996). In addition several studies have
reported an association of Leiden Factor V (FV) and
prothrombin (FII) G20210A with arterial thrombotic
disorders, especially in the association with the
juvenile cases (Kim and Becker 2003).
As a paradox, in long-living subjects the presence
of high-risk alleles, sometimes detected in the
homozygous form, for many polymorphisms related
to the cardiovascular diseases, has been documented
(Mari et al. 1996). In particular, in some studies
centenarians showed a paradoxically significantly
higher frequency of the high-risk genetic markers
Leiden factor V and G20210A mutation in prothrom-
bin gene, than young individuals (Mannucci et al.
1997; Sacchi et al. 1999), although they demonstrate
to be able in the escaping from the onset of the major
age-related diseases as AD.
In conclusion, all together our results indicate that
the state of hypercoagulability and the possession of
several high-risk alleles and well-known atherothrom-
botic risk markers appear to be compatible with
longevity and are not implied as risk factor in AD
development. However, considering the relative low
number of subjects analyzed in our study, these results
need to be confirmed in larger cohorts of subjects to
Table 1 FV 1691 G?A (FV LEIDEN) Genotypic and allelic frequencies of polymorphisms G1691A of Factor V in 95 patients with
AD, 106 nonagenarians and 65 healthy young subjects
N Genotypic frequencies Allelic frequencies
G/G G/A A/A G A
Alzheimer’s 95 95.8% (91) 4.2% (4) 0% (0) 97.9% (186) 2.1% (4)
[90 years old subjects 106 96.2% (102) 3.8% (4) 0% (0) 98.1% (208) 1.9% (4)
Young subjects 65 96.9% (63) 3.1% (2) 0% (0) 98.5% (128) 1.5% (2)
Table 2 FII 20210 G?A Genotypic and allelic frequencies of polymorphism G20210A of prothrombin gene observed in 95 patients
with AD, 106 nonagenarians and 65 healthy young subjects
N Genotypic frequencies Allelic frequencies
G/G G/A A/A G A
Alzheimer’s 95 94.7% (90) 5.3% (5) 0% (0) 97.4% (185) 2.6% (5)
[90 years old subjects 106 95.3% (101) 4.7% (5) 0% (0) 97.6% (207) 2.4% (5)
Young subjects 65 96.9% (63) 3.1% (2) 0% (0) 98.5% (128) 1.5% (2)
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definitively exclude that Leiden Factor V G169A and/
or Prothrombin G20210A polymorphisms might have
a role in successful or unsuccessful aging.
On the other hand, it is well known that the
protection or susceptibility effect of a single poly-
morphism might be modulate both as additive or
synergic and antagonistic influence by the presence of
other polymorphisms in genes involved in the same
metabolic or functional pathway. In this view, the
interaction of the analysed polymorphisms with other
functionally relevant genetic variants of coagulation
and of the strictly related complement cascade should
be considered in future studies. As reviewed by
Amara et al. (2008) both cascades contain series of
serine-proteases with evidence of some shared acti-
vators and inhibitors. Factor XIIa is able to activate
C1q, and thereby the classical pathway of comple-
ment. Besides thrombin, generated at inflammatory
sites in response to complement activation, is
involved in a negative feedback loop preventing
thrombosis during inflammation. Finally the comple-
ment activation product C5a has also been reported to
induce tissue factor (TF) activity and may activate the
exogenous (TF-dependent) coagulation pathway.
This seems to be more relevant considering that
two independent genome-wide association studies
(Lambert et al. 2009; Seshadri et al. 2010) have
recently demonstrated that the rs6656401 SNP of the
complement component (3b/4b) receptor 1 influenc-
ing a reduced clearance of complement-opsonized
Ab42 immune complexes might be involved as a
major genetic risk factor for late onset AD. So an
increased complement activity due to circulating IC
persistence might enhance coagulation cascade
trough the complex interaction summarised above.
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